Table.

Summary of clinical, metabolic, and genomic characteristics and potential therapeutic strategies of the metabolic pathway subtypes of HCC.

Subtype	Cluster 1	Cluster 2	Cluster 3	Cluster 4
Clinical	Good prognosis (5-year RFS, 64%); more BCLC A	Good prognosis (5-year RFS, 58%); multiple tumor.numbers	Poor prognosis (5-year RFS, 29%); bigger tumor size; vascular invasion	Good prognosis (5-year RFS, 47%)
Genomic	Frequent CNV gain in TP53 pathway	Frequent CNV and SNV	Dysregulation of cancer stem genes	N/A
Metabolic Features	Dysregulation of glycolytic genes and intermediate metabolites	Dysregulation of amino acid genes and intermediate metabolites	Dysregulation of lipogenesis genes and intermediate metabolites	Dysregulation of glycolytic genes and intermediate metabolites
Treatment	Clofazimine; glycolysis inhibitors	Anti-PD-1	Disulfiram; lipid synthesis inhibitors	Clofazimine; glycolysis inhibitors

CNV, copy-number variation; SNV, single-nucleotide variants; RFS, relapse-free survival; N/A, not available.